Galapagos « Terug naar discussie overzicht

Overname van....Gilead....?

3 Posts

Omlaag ↓

diederique 22 september 2016 21:19

kan zomaar gebeuren...

.....The latest idea? That the Dublin drugmaker may target Gilead, whose $107 billion market cap is quite a ways off
of the heights it reached last year.

www.fiercepharma.com/pharma/allergan-...

diederique 23 september 2016 00:25

Will Gilead Make a Good Fit for Allergan?

Allergen’s surprise interest emerged without any earlier indications of interest in companies focused on NASH or liver diseases. Given the backdrop of recent acquisitions, the market is abuzz with rumors about Gilead being the next potential target for Allergan.

www.investopedia.com/news/will-gilead...

diederique 23 september 2016 21:54

Allergan joins a growing field of companies intent on conquering NASH, which include Gilead Sciences Inc. GILD, -0.10% , Bristol-Myers Squibb Co. BMY, +0.23% , Intercept Pharmaceuticals Inc. ICPT, -2.42% , Galmed Pharmaecuticals Ltd. GLMD, -1.64% , Astra-Zeneca Plc AZN, -0.88% and Novartis AG NVS, -0.53% , among others, according to BioMedTracker.

www.marketwatch.com/story/allergan-is...

3 Posts

Aantal posts per pagina: 20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd	7 feb 2025 17:35
Koers	22,080
Verschil	-0,200 (-0,90%)
Hoog	22,460
Laag	21,960
Volume	65.330
Volume gemiddeld	112.448
Volume gisteren	77.505

Galapagos nieuws

23 jan	Barclays zet Galapagos op de verkoopl...
19 jan	IMCD uitblinker op goedgeluimd Damrak
09 jan	Van Lanschot: belangrijkste wending o...
08 jan	Mat begin beursdag vol nieuws van Gal...
08 jan	Galapagos wil opsplitsen in twee beur...	1
07 dec	Galapagos: bemoedigende nieuwe result...
20 nov	Kepler Cheuvreux zet Galapagos op ver...
05 nov	Klinische resultaten Galapagos steune...
04 nov	Deutsche Bank verlaagt koersdoel Gala...
02 nov	Financials en Shell doen goede zaken ...

Meer ››